You live in a mostly 2D world, but the map in your brain charts the places you’ve been in 3D – Massive Science

Most of us will get lost from time to time. But, nevertheless, our brains are actually pretty amazing at navigating. Even when you zone out on your daily commute, your brain is still able to get you there safely. This is thanks in part to your place cells.

Place cells are brain cells that respond to a particular location in the environment and become active when you are in that location. Researchers discovered them by putting rats in a square chamber and watching them run around. They monitoredwhen and where the rats' place cellswere active. By doing this, they could determine what location each place cell was responding to, called the cell's "place field." These place fields are usually circles of 15-25 inches in diameter for rats and mice.

These experiments taught us a lot about how place cells work, but they are not a great representation of the real world. A barren, square, white box is an unlikely environment for a rat, let alone a human, to encounter in the wild. How do your place cells represent locations in a real life, 3D world?

The 3D lattice used in the experiment

Grieves et al 2019. "The place-cell representation of volumetric space in rats."

Roddy M. Grieves, a neuroscientist at University College London, has designed a new rat navigation experiment to answer this question. Hebuilt a cubic lattice, a 3D grid that the rats could climb in any direction they pleased. They couldnt just move along the floor, but also vertically up and down.

Grieves and his colleagues wondered what the place fields of place cells would look like in such an environment. They posed two hypotheses. The first was that the place field might now look like cylinders, so one place cell would respond to a location parallel to the ground, regardless of high in the lattice the rate had climbed. The second was that the place fields would become spheres, so the place cell would take height into account and only respond when the rat was at a particular location along the ground and at a particular height. This hypothesis comes from research in Egyptian fruit bats, whose place cells have such spherical place fields.

The researchers discovered that place cells in rats roughly followed the second hypothesis: their place fields took the shape of elongated spheres, like rugby balls. The elongation was always along one of the three directions the rat could run in the wire frame lattice. Generally speaking, the place fields were more stretched in the vertical direction than they were horizontally. This is important, because it means that the cells are less accurate in this direction. In other words, the place cells were less precise in knowing how far up the rat was in space than where it was within the lattice on the ground.

This may be because rats are more inclined to move horizontally than vertically. Of course they can climb, but they tend to spend most of their time walking along the floor. Their place cells may just not be optimized for vertical movement. Another reason the place cells may be worse in the vertical direction is that it is physically harder for the rats to run in this direction. This makes it more difficult for them to gauge how far theyve traveled.

This research may give us an insight how the human brain performs navigation, because the human hippocampus, which is critical to navigation, is similar to that of rats. And like rats, we are mammals who generally navigate predominantly in a 2D environment. However, our environment is becoming more and more 3D, with tall buildings, bridges, and underground structures.

These findings in rats suggest that our brains are mainly tuned to the direction were used to navigating: parallel to the ground. Since most of our world is laid out flat in front of us, like the floors in buildings, this makes sense. Even if we fly a plane or drive a submarine we are often still moving parallel to the ground. But this might not always be the case.

Examples of different shaped 3D place fields, with (L-R) one, two, three, or four place fields visible.

Grieves et al 2019. "The place-cell representation of volumetric space in rats."

One possible future scenario where humans would be truly navigating in 3D would be in outerspace. Without gravity there would not be a single direction that would be relatively easier or harder to move along, such as the vertical axes for the rats. As of now, we dont know what our place cells might do in such a situation and, more importantly, whether we would be able to navigate around as efficiently as we do in our 2D world.

Both on Earth and in space the design of the environment ultimately has a big impact on our ability to navigate. We are better able to navigate if there are plenty of landmarks around to tell us where we are. We can orient ourselves more easily if a space is not symmetrical. We also navigate better through an environment if we have experienced it from different angles.

Knowing how we find our way around, especially in complex environments, has major implications for the fields of architecture and urban design. It should also be taken into account by engineers and anyone who designs the spaces around us. The goal of research into navigation is not just to understand how our brain works, but also to use this information to make the world around us more suitable for navigation.

This collaboration between neuroscience and urban design is combined in the burgeoning idea of conscious cities: environments built to take the needs and behaviors of humans into account. As our cities are getting larger and more complex, neuroscience research will become increasingly important in guiding their design.

Follow this link:
You live in a mostly 2D world, but the map in your brain charts the places you've been in 3D - Massive Science

What Are the Neural Roots of Procrastination? – Psychology Today

Youd like to be on time, but no matter how hard you try, youre never less than fiveminutes late. Youve promised to meet a friend for coffee, but to your dismay, you realize theres no way youll get there within anywhere near that five-minute average.How are you going to explain your lateness this time?

Well, you can come up with all sorts of reasons, from traffic to an unexpected phone callor the need to answer an emergency email. However, this particular episode of lateness relates to a larger problem you have with procrastination. Deadlines come up at work or in your home life, but they dont seem real until the actual date or time is upon you.

Psychology tries to explain procrastination through a variety of theories. From the psychodynamic point of view, your constant stalling is due to a neurotic and self-defeating need to fail. Being late and missing mostdeadlines ensures that you will be regarded as unreliable, almost guaranteeing failure at work and in relationships.

Being overly narcissistic can be another source of procrastination. You love waiting until the last minute so you can make a grand entrance as everyone else is left waiting and wondering where you are.

Its also possible, though, that your brain is wired to make lateness an inherent part of your psychological makeup. According to a new study by Shunmin Zhang and colleagues (2019) of Southwest University, Chongqing, China, It is generally accepted that procrastination is a voluntary but irrational delay of intended courses of action (pp. 1-2). The authors summarize contemporary personality theories, which place the blame not on neurotic needs but on the personality traits of low self-control and high impulsivity. However, the Chinese research team believes that there are cognitive explanations of procrastination that are just as, if not more, valuable in understanding the causes of procrastination.

To understand the brain's role in procrastination, Zhang et al. begin by describingthe contrasting explanation of two cognitive approaches. The emotion-regulation perspective, as the term implies, proposes that people procrastinate when they let their short-term goal of putting off something they dont want to do outweigh the long-term benefits of getting the task accomplished. In other words, the benefits of avoiding task-induced aversiveness trump the benefits of the delayed rewards the task can yield (p. 2).

Conversely, motivation-based theory regards procrastination as due to an increase in motivation to act as the deadline looms. This theory, referred to as temporal discounting, proposes that the further away an event is temporally, the less impact it has (p. 2). You dont see that deadline of three weeks away as something to worry about, and only act when the weeks dwindle to days or even hours. As compelling as these cognitive approaches may seem on their own, though, the authors believe both motivation and emotion form part of the procrastination picture.

The Chinese authors believe, instead, that these psychological theories together can provide the answers in one temporal decision model. Whether you act now or in the future depends on whether the motivation to act outweighs the motivation to avoid. Heres where your brain steps in to explain your constant lateness. The emotional aversiveness piece of procrastination comes from the activity of the parahippocampus (involved in memory), which remembers how aversive the task was in the past (i.e., you really dont like that friend you were supposed to meet for coffee).Indeed, Zhang et al. maintain that this tiny piece of brain tissue provides one of the most solid neural underpinnings underlying trait procrastination (p. 11).

This is because the parahippocampus additionally communicates with other neighboring brain regions in the limbic system. In procrastinators, this whole region works together to amplify an events aversiveness. In people who dont procrastinate the brain sends out fewer emotional alarms about the upcoming and potentially unpleasant task.

Next, the temporal discounting piece in procrastination kicks in, leading procrastinators to feel less motivated to get started on an event that seems far away. Zhang et al. cite research showing that procrastinators may have less neural tissue in the prefrontal area of the brain (involved in planning and impulse control), making it more difficult for them to self-regulate their use of time. Without the ability to self-regulate, youll find it more difficult to pace yourself as you try to achieve a goal within the allotted time limits. Chronic procrastinators can only think of is how boring, frustrating, or unfulfilling the task will be until the inevitable comes along and they have no choice but to tackle it. Again, returning to the meeting with your friend, you may have started with plenty of time to get there at the appointed hour, but as the clock ticked down, you became more reluctant to get yourself organized enough to actually get out the door.

Although you might be tempted to use the temporal decision theory as an excuse for your lateness, or even to attribute your chronic lateness to insufficient gray matter, there are other ways to interpret this neuroscience-basedexplanation. If you know youre a procrastinator, you dont have to give in to the faulty brain waves youre receiving. Recognize the need to learn from your experiences and put into your memory bank the problems procrastination has caused you. Conversely, realizing that you tend to emphasize the negative aspects of tasks that you know must be completed, try to frame them in a more positive light. The basic premises of cognitive behavioral therapy can also be of use. Give yourself some basic rewards for getting things done on time, replacing your negative with positive associations.

To sum up, chronic procrastination may have its roots in many sources. By knowing the brain structures potentially underlying the inability to look a deadline in the eye, you dont have to suffer a lifetime of lateness.

Read more:
What Are the Neural Roots of Procrastination? - Psychology Today

Global Neuroscience Antibodies and Assays Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – Breaking News Updates

The Neuroscience Antibodies and Assays Market report gives a purposeful depiction of the area by the practice for research, amalgamation, and review of data taken from various sources. The market analysts have displayed the different sidelines of the area with a point on recognizing the top players (Thermo Fisher, Abcam, Bio-Rad, Merck, Cell Signaling Technology, Genscript, Rockland Immunochemicals, BioLegend, Santa Cruz Biotechnology, Roche, Siemens) of the industry. The Neuroscience Antibodies and Assays market report correspondingly joins a predefined business market from a SWOT investigation of the real players. Thus, the data summarized out is, no matter how you look at it is, reliable and the result of expansive research.

This report mulls over Neuroscience Antibodies and Assays showcase on the classification, for instance, application, concords, innovations, income, improvement rate, import, and others (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers) in the estimated time from 20192025 on a global stage. In like manner, the overall Neuroscience Antibodies and Assays market report reveals knowledge identified with the type of product, its applications, customers, prime players, and various components agreeing with the account. This first data demonstrates critical contenders and their definite picture of the general Neuroscience Antibodies and Assays market. Other than this, the report further demonstrates expected market power, challenges, and prospects in the Neuroscience Antibodies and Assays market.

Request for Sample Report @http://www.marketresearchstore.com/report/global-neuroscience-antibodies-and-assays-market-2018-by-392257#RequestSample

The report gives a broad explanation of the presence of the Neuroscience Antibodies and Assays market in different regions and countries. With an extensive regional analysis of the Neuroscience Antibodies and Assays market, the research analysts make an attempt to unveil hidden growth prospects available for players in different parts of the world. They accurately estimate market share, CAGR, production, consumption, price, revenue, and other crucial factors that indicate the growth of regional markets studied in the report. They also shed light on the presence of prominent players in regional markets, and how it is making a difference in the growth of the regional markets. The main objectives of the research report elaborate the overall market overview on Neuroscience Antibodies and Assays market dynamics, historic volume and value, robust market methodology, current & future trends, Porters Five Forces Analysis, upstream and downstream industry chain, new technological development, cost structure, government policies & regulations, etc.

Neuroscience Antibodies and Assays Market report segmentation on Major Product Type:Consumables, Instruments

The global version of this report with a geographical classification such as

North America (the United States, Canada, and Mexico)Europe (Germany, UK, France, Italy, Russia, Spain, and Benelux)Asia Pacific (China, Japan, India, Southeast Asia, and Australia)Latin America (Brazil, Argentina, and Colombia)The Middle East and Africa

Reason to buy Neuroscience Antibodies and Assays Market Report : 1) Breakdown of the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.2) The Neuroscience Antibodies and Assays competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.3) Describe Neuroscience Antibodies and Assays sales channel, distributors, customers, research findings and conclusion, appendix and data source.4) The details of the competitive landscape outlined in this report are likely to provide an analysis of the prominent industry vendors, their growth profiles, strategies, and tactics, etc., that would help investors in decision-making.5) To project the size of Neuroscience Antibodies and Assays submarkets, with respect to key regions (along with their respective key countries).6) To strategically profile the key players and comprehensively analyze their growth strategies.7) Focuses on the key global Neuroscience Antibodies and Assays players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in the next few years.

This report contributes an overall summary of the global Neuroscience Antibodies and Assays market, including business perspectives, market strategies, assembles data related to various business firms, its year of establishment, contact information, market outline, sales revenue, industry segments, the business most prestigious location, and regional presence. The report includes several plans and policies related to the Neuroscience Antibodies and Assays industry, moreover, it describes the management process, product appearance, manufacturing cost, and market volume. In addition, the global Neuroscience Antibodies and Assays market report implicates financial usage, the quantity of product, chain format, demand and supply ratio. This report justifies the various business trends followed by the marketing sectors as well as the distributors of the Neuroscience Antibodies and Assays industry.

Inquiry for Buying a report @http://www.marketresearchstore.com/report/global-neuroscience-antibodies-and-assays-market-2018-by-392257#InquiryForBuying

The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, the growth rate of the Neuroscience Antibodies and Assays market in 2023 is also explained. Finally, the possibility analysis of new project investment is done in the report, which contains a comprehensive SWOT analysis of the Neuroscience Antibodies and Assays market.

Sorry! The Author has not filled his profile.

See the original post:
Global Neuroscience Antibodies and Assays Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Breaking News Updates

Some battle tested neuroscience vets are going all out on early onset dementia with a $44M launch round to build the team – Endpoints News

Anyone who specializes in neurosciences R&D has to prepare themselves for some frustration along the way. And the team at Arkuda Therapeutics can tell you all about it.

The CEO and co-founder is Gerhard Koenig, who you may recall headed up the team at Quartet Medicines, which worked on neuronal and inflammatory cells, until they folded the shop after running into a blind alley. Before that, he was CSO at Forum, which Deborah Dunsire now CEO at Lundbeck had helmed as it tried to break new ground in Alzheimers and schizophrenia.

It didnt work out either.

But even though Atlas closed the checkbook on Quartet, Bruce Booth never blamed the crew. You want to try something cutting edge here, you pay your money and you take your chances. And sometimes you write off your losses.

Thats biotech.

So now Koenig and some of the execs hes known along the way are back, knocking the door on a new approach to neurodegeneration, another high-risk, high-reward play where they are looking to break new ground. And Booth has been bankrolling the incubator work in hopes of seeing a new venture fly.

Unlock this story instantly and join 65,900+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read this article:
Some battle tested neuroscience vets are going all out on early onset dementia with a $44M launch round to build the team - Endpoints News

Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference – Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, including poster presentations on November 18th and 19th.

The company will showcase ImmunoID NeXT, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

Following is a list of abstracts that will be presented at the meeting.

Scientific Poster Presentations

Poster Number

Title & Presenter

Day & Time

Location

A19

HLA allele-specific loss of heterozygosity detectionusing augmented exome capture approach

Presenter: Rachel Marty Pyke, Ph.D.

November 18:12:30 PM 3:00 PM

Back Bay

B18

Exome scale liquid biopsy monitoring of putativeneoantigens and genomic biomarkers in patientson anti-PD-1 therapy in squamous cell carcinoma ofthe head and neck

Presenter: Charles Abbott, Ph.D.

November 19:4:30 PM 7:00 PM

Back Bay

Personalis will also be exhibiting during the conference (Exhibit # 10). Representatives will be available to answer questions about the companys cancer immunogenomics services.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response. The companys NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit http://www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Read this article:
Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference - Business Wire

I have a PhD in immunology and this is how I keep my daughter from getting sick during the winter – Business Insider

captionFlu season is here, which means families need to take extra precautions to keep children from getting sick.sourceGetty

Flu season is here. But Im not all that worried. I have a PhD in immunology and have put that training to good use in protecting my now 5-year-old daughter from getting sick. I take all the standard precautions to safeguard against the sniffles, by vaccinating and practicing sensible hand washing (while still largely avoiding hand sanitizers), but theres still a lot more to do to keep sickness at bay.

One issue that may affect your childs ability to fight infection is a Vitamin D deficiency. Vitamin D has a three-fold role in the immune system it fights infections and curbs autoimmune processes as well as inflammation. Vitamin D deficiency increases risks for a number of health issues, including repeatedly falling ill.

The main source of Vitamin D is exposure to sunlight. Vitamin D deficiency is somewhat common, and worsens in winter when people dont get outside as much.

Between 12% and 24% of infants, children, and adolescents are Vitamin D deficient, with breastfed babies being at a higher risk. The American Academy of Pediatrics (AAP) recommends that in their first year of life, babies get 400 IU of Vitamin D daily. The AAP advises parents to give an oral Vitamin D supplement to breastfeeding infants and to those who consume less than 1 liter of infant formula a day.

By conservative estimates, children and adolescents need 600 IU each day. Its ideal for children and adolescents to get Vitamin D from natural sources, experts say.

If youre concerned that your child isnt getting enough from sunlight exposure, or is showing warning signs like being tired or falling ill often, consult your pediatrician about a potential Vitamin D deficiency.

I give my daughter the recommended dose all year round with a probiotic called BioGaia that is fortified with Vitamin D.

Omega 3s play a crucial role in brain and vision development, and were just beginning to understand the role they play in the immune system. As with most things, getting some but not too much is prudent. Ensuring your childs diet has some omega 3s, either regularly through food including wild-caught salmon and walnuts or supplementing periodically is a good idea. A breastfeeding mom should also eat a generous amount of foods containing omega 3s so that the nutrients are transferred to the baby.

Part of my childs regular maintenance protocol is taking a probiotic Lactobacillus reuteri DSM 17938, marketed as Biogaia. Originally discovered in breastmilk, part of its potential protective mechanism is the broad spectrum of antibiotic (reuterin) it produces, which may limit colonization by pathogenic bacteria.

In small research studies, it has been shown to protect against both GI tract and respiratory infections, reduce colic in breastmilk fed infants, and potentially protect against cavities. Taken together, the evidence suggests the probiotic microorganism may improve health in a variety of contexts.

Given the limited evidence, there is no recommendation for regular use. But since Biogaias safety is well-established and the cost is reasonable (about $30 for a two-month supply), I elected to give it regularly to my child since birth, and will continue doing so. (Be aware: the majority of probiotics have minimal to no research to back up their claims).

Turmeric has been used for medicinal purposes in India for centuries. As modern science is now discovering, its main component curcumin has anti-inflammatory, anti-viral, anti-microbial, and anti-cancer properties. It could potentially help in fending off both viral and bacterial infections and combat the deleterious effects of inflammation.

However, drinking a turmeric extract in water (in say, a latte or smoothie) is close to useless because it absorbs poorly when dissolved in water. What little is absorbed is then rapidly eliminated by the liver.

Turmeric should be dissolved in oil, ideally, for absorption. For maximum effect, pair it with piperine, a component of black pepper that prevents the rapid elimination.

When my daughter is ill, I serve her either a home-brew of turmeric in coconut oil with black pepper (taken with manuka honey, milk, or both), or a supplement that contains liposome-encapsulated turmeric plus piperine three to four times a day until her fever breaks.

Elderberry extracts have also been used medicinally for centuries. In studies in vitro, and in mice, and humans, elderberry has been shown to help reduce the severity and length of the flu, and can help in fighting other viral infections too.

Some parents go so far as to give elderberry to their children every day. However, this is both unnecessary and potentially dangerous: Elderberry has medicinal properties that could actually interfere with normal functioning. For example, elderberry extracts inhibit functioning of ribosomes, which are required for protein production. They may exacerbate autoimmune diseases and their long-term safety has not been studied.

Consult with your pediatrician to determine the appropriate dose for your child.

How has all this helped? While it is impossible to be sure, I can say for certain that my daughter has never had ear infections, colic, or constipation. Weve almost never had an infection that required antibiotics. Illness rarely strikes, and when it does, it subsides quickly. We have gone years without a fever, and when it comes, it usually resolves within 24 hours.

Thats good enough for me.

Here is the original post:
I have a PhD in immunology and this is how I keep my daughter from getting sick during the winter - Business Insider

Robert Ferris, MD, on Immunotherapy Transforming Cancer Treatment – Cancer Network

Robert Ferris, MD, from UPMC Hillman Cancer Center, discusses the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), and how immunotherapy will continue to transform cancer treatment.

Transcript:

Ive been attending the plenary session by Dr. Ron Germaine and Dr. Finn won the Smalley award and the presidential session today with some promising young investigators.

Dr. Finn is really a giant of cancer immunology, in particular cancer immune-prevention. She received the Smalley award and gave us a couple of decades of target and vaccinating for cancer prevention. Dr. Ron Germaine has contributed to basic immunology and our understanding of triggering the immune response. And he has moved more into systems biology, trying to integrate 30, 40, 50 markers, tissue imaging in tumors in situ, and cautioning us not to get too far ahead with some of the single cell technologies and to recognize the way lymphocytes are laid out and move their ability to get around in the tumor. The infrastructure of a tumor may affect the quality of success of an immune response, So, as typical for someone of his contributions, it was really a mind-blowing presentation phenomenal video, very insightful. He continues to contribute to our understanding of immunology.

Junior investigators in the presidential symposium were really outstanding and gave us some amazing work into the microbiome. A scientist in training from Wake Forest talked about the CD47 thrombospondent pathway and how that eat me or dont eat me signal that cells have and tumor cells can modulate may impact the immune response to cancer. So, really some amazing work and we see the next generation coming with a very potent and informative stance as well. A great credit to SITC in identifying these junior folks, and a credit to their mentors as well.

Ive been coming to this meeting for over 15 years. I was here and one of the organizers 10 or 12 years ago when they were about 400 or 500 attendees. It is now 10-fold bigger. So, my hope is that is it is not another 1,000 people. One thing I like about this meeting is its collegiality, so hopefully it doesnt get too impersonal. I think a year from now, SITC has added the early-phase clinical trials, so it has been a nice addition bridging what AACR or ASCO have done. The relationship with NCI, the FDA, pharma, as well as translational and clinical scientists, it can only happen at SITC. There is no other meeting where this occurs. And I think that explains this huge influx in membership and attendees. Even though I tease a little bit that it can be getting too big, I think next year is likely to be a continuation of the trend, drawing in folks who have not gotten up every day thinking about immunology for years but now understand and recognize that they need to. SITC is really the form for transmitting information, basic mechanisms, biomarkers, and now clinical data from exciting clinical trials.

We really do feel like immunotherapy has the potential to cure so hopefully we will add safe, but effective combinations of immunotherapy. Obviously the PD-1 inhibitors with or without a CTLA-4 inhibitor have been the most effective as monotherapy or combinations. I think were all still waiting for that next big breakthrough, the next big leap forward, whether it is immune checkpoints or inflammatory agonists or other combinations for where immunotherapy will transform cancer treatment.

See the article here:
Robert Ferris, MD, on Immunotherapy Transforming Cancer Treatment - Cancer Network

Livestock Antibody Hub receives US $5.5 million to improve animal health – The Poultry Site

Researchers from The Pirbright Institute have been awarded US $5.5 million by the Bill & Melinda Gates Foundation to establish a Livestock Antibody Hub aimed at improving animal and human health globally. The ambitious programme of work will see extensive collaboration between multiple UK research organisations in order to utilise research outcomes in livestock disease and immunology to support human health as part of the One Health agenda.

Six leading scientists from Pirbright will be involved in the project, including Professor John Hammond, Professor Venugopal Nair, Dr Simon Graham, Dr Elma Tchilian, Professor Munir Iqbal and Dr Erica Bickerton. Their combined expert knowledge will drive the study of cattle, pig and poultry antibody responses at high resolution to expand our understanding of protective immunity in species that can also be used as models for a range of human infectious diseases.

The aim is to use Pirbrights expertise in livestock viral diseases, cutting-edge technology and unique high-containment facilities to bring antibody discovery, manipulation and testing up to the benchmark already seen in the immunological field for rodents and humans. This highly collaborative work will address the needs of the livestock research community whilst bridging the requirements of the vaccine industry.

A number of work programmes will focus on studying B cells and antibodies at multiple scales including gene expression, single cell function and the entire antibody response. Findings from this research will be used to drive vaccine selection and design and test antibody therapies with Pirbright ultimately acting as a Hub able to provide specific methods, access to animal models and the associated expertise to drive antibody research within the One Health agenda.

Research lead Professor John Hammond said, New technology has given us the opportunity to utilise these detailed antibody responses to make the next generation of vaccines and therapies, which will improve animal health and ultimately human health, as well as ensuring the security of our food supply.

Dr Doug Brown, Chief Executive of the British Society for Immunology, commented, The UK is a world leader in veterinary immunology research, and this transformative investment from the Bill & Melinda Gates Foundation will drive the next chapter of innovation in developing new treatments and prevention options against livestock diseases. This is the single biggest investment in the immunology of livestock in the UK from an international funder, and the British Society for Immunology will do all we can to support this collaborative initiative and help maximise its impact for the benefit of human and animal health.

More here:
Livestock Antibody Hub receives US $5.5 million to improve animal health - The Poultry Site

AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research’s Tumor Immunology…

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--AgilVax Inc., a biopharmaceutical company that discovers and develops targeted antibody-based therapeutics, announced today that preclinical data describing M5, the Companys monoclonal antibody targeting xCT, will be presented by Dr. Salameh at the American Association for Cancer Researchs Tumor Immunology and Immunotherapy Conference being held at the Boston Marriott Copley Place in Boston, MA.

Title:

Development of a monoclonal antibody targeting xCT/SLC7A11 expressed in metastatic cancer cells

Poster Session:

Poster Session B

Session Date:

Tuesday, November 19

Board Number (poster number):

B37

Time:

4:30 p.m. to 7:00 p.m.

Session Location:

Back Bay

We are pleased with our continued progress on developing multiple solutions to target cancer cells overexpressing xCT and thrilled to have the opportunity to showcase our advancements in a poster presentation at such a prestigious meeting, said Dr. Joseph Patti, President and CEO of AgilVax. Dr. Patti further stated, xCT overexpression occurs in several cancers leading to metabolic changes that reprograms cells for growth and progression. AgilVaxs antibody-based therapeutics have shown reduction of primary tumor formation and lung metastases illustrating the potential to create durable responses in patients suffering from colorectal and other metastatic cancers.

About AgilVax

AgilVax is a biopharmaceutical company that discover and develops targeted antibody-based products to treat multiple types of cancer. The Company has three development programs; an unmodified monoclonal antibody (mAb) targeting xCT, an antibody-drug conjugate targeting xCT, and AX09, a VLP-based xCT vaccine currently in cGMP production.

For more information, please visit http://www.agilvax.com

Originally posted here:
AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research's Tumor Immunology...

Immunology Market 2019 production, revenue, price, market share and growth rate upto 2025 – Press X Now

The Immunology market report offers an in-depth analysis of the on-going trends, Immunology Market drivers, different opportunities and high-growth areas which would help clients to articulate Immunology market strategies according to the current and future industry trends. The Immunology market study also covers the regional and global analysis of this industry. Furthermore, it examines and meanwhile, represents the worldwide Immunology market size of the significant players in each region around the different corner of the world.

Request a sample copy of this report at: https://marketresearchexpertz.com/report/global-immunology-market-28675#request-sample

Reportedly, the global Immunology market report accounted for xx billion in 2018 and it is projected to gather xx billion US$ by 2026, along with a growing CAGR of xx % during the forecast timeframe. Several factors including increasing demand for upgrading of the Immunology market, rising demand of the industry from developing economies, and expanding the use of Immunology market over distinct sectors are propelling the universal market.

Key Manufacturers functioning in this market are:AbbVieAmgenF. Hoffmann-La RocheJohnson & JohnsonBionor PharmaCelgeneCellectar BioscienceseFFECTOR Therapeutics

Global Immunology market segregation by type:Immuno BoostersImmunosuppressants

The Application of Immunology market can be split into:Autoimmune DiseasesOncologyOrgan TransplantationOthers

The elaborated study delivers a brief appraisal of the Immunology market that helps stakeholders to gain a solid base in this industry. The main motive of the Global Immunology market 2019 report is to offer industry investors, customers, and company officials with important statistics to assist them to create reliable industrial decisions related to the essential opportunities in the Immunology market.

This research study also pinpoints business insights and offers an analysis of the extremely significant trends that are anticipated to affect the Immunology market outlook from the year 2019 to 2026. The report also incorporates the production capacity, value chain structure, raw material sources as well as suppliers, import/export, product portfolios, and technology adoptions. Their financial status is also analyzed in the worldwide Immunology market report which studies pricing structure, growth rate, gross margin, fiscal ratios, product value, cash flow, sales volume and much more. The evaluation of the Immunology market also promotes clients to grab a clear understanding of the Immunology industry position at global level, strengths and weakness of their rivals too.

Browse More Details: https://marketresearchexpertz.com/report/global-immunology-market-28675

The research report on the Global Immunology market will surely help major market players as well as new entrants to understand the international industry in detail. Moreover, this study also encourages industry vendors to decide their business strategies and work hard to achieve their proposed business aims.

Read the original post:
Immunology Market 2019 production, revenue, price, market share and growth rate upto 2025 - Press X Now